Vaughan & Co Securities’s Bristol-Myers Squibb BMY Stock Holding History

Vaughan & Co Securities’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$849K	Sell	14,738 -912	-6%	-$52.4K	0.4%	24
2026 Q1	$949K	Sell	15,650 -593	-4%	-$34.6K	0.49%	20
2025 Q4	$876K	Sell	16,243 -400	-2%	-$19.2K	0.45%	21
2025 Q3	$751K	Buy	16,643 +4,959	+42%	+$232K	0.4%	28
2025 Q2	$541K	Sell	11,684 -22	-0.2%	-$1.08K	0.31%	40
2025 Q1	$714K	Sell	11,706 -4,325	-27%	-$252K	0.44%	30
2024 Q4	$907K	Sell	16,031 -591	-4%	-$33K	0.55%	20
2024 Q3	$860K	Hold	16,622	–	–	0.51%	23
2024 Q2	$690K	Buy	+16,622	New	+$744K	0.44%	26
2020 Q2	–	Sell	-720	Closed	-$40.1K	–	57
2020 Q1	$40.1K	Hold	720	–	–	0.05%	91
2019 Q4	$46.2K	Buy	+720	New	+$41.2K	0.04%	92

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vaughan & Co Securities's BMY Position: Q2 2026 in Review

Vaughan & Co Securities reduced its Bristol-Myers Squibb (BMY) stake by 5.8% in Q2 2026, selling an estimated $52.4K and leaving 14,738 shares worth $849K. The position accounts for 0.4% of the portfolio, ranked #24.

Vaughan & Co Securities first reported a position in BMY in Q4 2019 and has held it in 11 quarters since. The position peaked at $949K in Q1 2026. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Vaughan & Co Securities held 14,738 shares of Bristol-Myers Squibb worth $849K as of Q2 2026.
Vaughan & Co Securities sold 912 Bristol-Myers Squibb shares in Q2 2026, an estimated $52.4K.
Bristol-Myers Squibb made up 0.4% of Vaughan & Co Securities's portfolio in Q2 2026, its #24 holding.
Vaughan & Co Securities first reported a position in Bristol-Myers Squibb in Q4 2019 and has held it in 11 quarters since.
Vaughan & Co Securities's Bristol-Myers Squibb position peaked at $949K in Q1 2026.
2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Vaughan & Co Securities's 13F filing for Q2 2026, filed 3 Aug 2026.